2023
1559P PD-L1 expression as a negative predictive biomarker in advanced esophageal squamous cell cancer treated with chemotherapy alone: A KMSubtraction derived analysis
Sachdeva M, Zhao J, Zhu K, Yap D, Wong N, Barr N, Sundar R. 1559P PD-L1 expression as a negative predictive biomarker in advanced esophageal squamous cell cancer treated with chemotherapy alone: A KMSubtraction derived analysis. Annals Of Oncology 2023, 34: s873. DOI: 10.1016/j.annonc.2023.09.1471.Peer-Reviewed Original Research
2022
ASO Author Reflections: Combination Intra-Peritoneal and Systemic Chemotherapy for Gastric Cancer with Peritoneal Metastases
Chia D, Ang J, Sundar R, Kim G, Shabbir A, So J, Yong W. ASO Author Reflections: Combination Intra-Peritoneal and Systemic Chemotherapy for Gastric Cancer with Peritoneal Metastases. Annals Of Surgical Oncology 2022, 29: 8606-8607. PMID: 36192514, DOI: 10.1245/s10434-022-12102-1.Peer-Reviewed Original ResearchThe phenotype and value of nerve conduction studies in measuring chemotherapy-induced peripheral neuropathy: A secondary analysis of pooled data
Wang M, Bandla A, Sundar R, Molassiotis A. The phenotype and value of nerve conduction studies in measuring chemotherapy-induced peripheral neuropathy: A secondary analysis of pooled data. European Journal Of Oncology Nursing 2022, 60: 102196. PMID: 36067640, DOI: 10.1016/j.ejon.2022.102196.Peer-Reviewed Original ResearchConceptsChemotherapy-induced peripheral neuropathyMeasuring chemotherapy-induced peripheral neuropathyNerve conduction studiesQuality of lifePeripheral neuropathySecondary analysisSecondary analysis of pooled dataPerformance of nerve conduction studiesNerve conduction study resultsNerve conduction study parametersTime points of assessmentInitiation of chemotherapyPatient-reported symptomsOxaliplatin-based chemotherapyPooled dataClinical examination outcomeAnalysis of pooled dataConduction studiesCIPN assessmentMonitoring peripheral neuropathyNeurotoxic chemotherapyProspective studyClinical examinationSensory nervesChemotherapy
2021
Abstract CT211: Personalized, rational, efficacy-driven chemotherapy dosing via an artificial intelligence system (PRECISE): A protocol for the PRECISE CURATE.AI pilot clinical trial
Teo C, Tan B, Tadeo X, Peng S, Soh H, Du S, Luo V, Bandla A, Sundar R, Ho D, Kee T, Blasiak A. Abstract CT211: Personalized, rational, efficacy-driven chemotherapy dosing via an artificial intelligence system (PRECISE): A protocol for the PRECISE CURATE.AI pilot clinical trial. Cancer Research 2021, 81: ct211-ct211. DOI: 10.1158/1538-7445.am2021-ct211.Peer-Reviewed Original ResearchTumor marker levelsRandomized controlled trialsChemotherapy doseSolid tumorsDrug doseDosing recommendationsMarker levelsAmerican Association for Cancer Research annual meetingsSignificant dose changesTumor marker measurementsCapecitabine-based chemotherapyMetastatic solid tumorsOptimal chemotherapy dosingRecruitment of patientsFrequent toxicitiesOpen-labelCA19-9Dose changesCohort expansionTumor markersSingle-armSuboptimal efficacyProportion of participantsChemotherapySerial measurementsThe impact of prior therapies on outcomes with trifluridine/tipiracil (FTD/TPI) in the phase III TAGS trial.
Shitara K, George B, Taieb J, Sundar R, Fakih M, Makris L, Benhadji K, Ghidini M. The impact of prior therapies on outcomes with trifluridine/tipiracil (FTD/TPI) in the phase III TAGS trial. Journal Of Clinical Oncology 2021, 39: 247-247. DOI: 10.1200/jco.2021.39.3_suppl.247.Peer-Reviewed Original ResearchFTD/TPI treatmentSafety profileAdverse eventsSafety of FTD/TPIGastroesophageal junction cancerThird-line chemotherapySecond-line treatmentPost hoc analysisHematologic toxicityOS benefitChemotherapy regimensJunction cancerSurvival benefitEfficacy benefitsFTD/TPIRamucirumabTagging trialsPlaceboPaclitaxelPrior treatmentAssociated with benefitsHoc analysisInfluence outcomesChemotherapySubgroup A
2020
A Limb Hypothermia Wearable for Chemotherapy-Induced Peripheral Neuropathy: A Mixed-Methods Approach in Medical Product Development
Binder J, Unver E, Clayton J, Burke P, Paxman R, Sundar R, Bandla A. A Limb Hypothermia Wearable for Chemotherapy-Induced Peripheral Neuropathy: A Mixed-Methods Approach in Medical Product Development. Frontiers In Digital Health 2020, 2: 573234. PMID: 34713046, PMCID: PMC8521967, DOI: 10.3389/fdgth.2020.573234.Peer-Reviewed Original ResearchChemotherapy-induced peripheral neuropathyPeripheral neuropathyDose-limiting side effectTaxane-based chemotherapyLarge-scale efficacy trialsChemotherapy-induced alopeciaPrevention of chemotherapy-induced alopeciaHigh-risk natureMixed-methods approachIntegration of evidence-basedCIPN severityClinical trialsDevice designDesign inputsEfficacy trialsChemotherapyScalp coolingMultidisciplinary approachEvidence-based approachNeuropathyExpert focus groupEarly dataMedical device designAdditive manufacturingConcomitant limb cryocompression and scalp cooling to reduce paclitaxel-induced neuropathy and alopecia.
Sundar R, Magarajah G, Ow S, Chan G, Choo J, Eng L, Wong A, Vijayan J, Hairom Z, Ang E, Paxman R, Wilder-Smith E, Thakor N, Lee S, Bandla A. Concomitant limb cryocompression and scalp cooling to reduce paclitaxel-induced neuropathy and alopecia. Journal Of Clinical Oncology 2020, 38: e24157-e24157. DOI: 10.1200/jco.2020.38.15_suppl.e24157.Peer-Reviewed Original ResearchChemotherapy-induced peripheral neuropathyPaclitaxel-induced neuropathyChemotherapy-induced alopeciaPost-chemotherapyScalp coolingAdverse effects of paclitaxelPreservation of nerve functionWeekly paclitaxel chemotherapyToxicity of paclitaxelEffects of paclitaxelReducing chemotherapy-induced alopeciaBreast cancer patientsLimb hypothermiaProof-of-concept studyPaclitaxel chemotherapyHypothermia trialTransient erythemaNo significant differencePatient toleranceRandomized studyNerve functionPre-chemotherapyPeripheral neuropathyChemotherapyCancer patients
2019
Safety and tolerability of cryocompression as a method of enhanced limb hypothermia to reduce taxane-induced peripheral neuropathy
Bandla A, Tan S, Kumarakulasinghe N, Huang Y, Ang S, Magarajah G, Hairom Z, Lim J, Wong A, Chan G, Ngoi N, Ang E, Lee Y, Chan A, Lee S, Thakor N, Wilder-Smith E, Sundar R. Safety and tolerability of cryocompression as a method of enhanced limb hypothermia to reduce taxane-induced peripheral neuropathy. Supportive Care In Cancer 2019, 28: 3691-3699. PMID: 31811482, PMCID: PMC7316694, DOI: 10.1007/s00520-019-05177-2.Peer-Reviewed Original ResearchConceptsNerve conduction studiesTotal Neuropathy ScoreFrozen glovesTaxane chemotherapyNeuropathy scorePeripheral neuropathyDose-limiting toxicityConcomitant with chemotherapyTaxane-induced peripheral neuropathySeverity of neuropathySensory nerve amplitudesPrevention of neurotoxicitySkin temperature reductionLimb hypothermiaMonths post-chemotherapyPaclitaxel chemotherapyNerve amplitudeMotor amplitudeSevere neuropathyPost-chemotherapyUndesired side effectsChemotherapyCancer patientsNeuropathySide effectsRisk factors for chemotherapy‐induced peripheral neuropathy in patients receiving taxane‐ and platinum‐based chemotherapy
Molassiotis A, Cheng H, Leung K, Li Y, Wong K, Au J, Sundar R, Chan A, De Ng T, Suen L, Chan C, Yorke J, Lopez V. Risk factors for chemotherapy‐induced peripheral neuropathy in patients receiving taxane‐ and platinum‐based chemotherapy. Brain And Behavior 2019, 9: e01312. PMID: 31063261, PMCID: PMC6576180, DOI: 10.1002/brb3.1312.Peer-Reviewed Original ResearchConceptsChemotherapy-induced peripheral neuropathyDevelopment of chemotherapy-induced peripheral neuropathyHistory of neuropathyRisk factorsPeripheral neuropathyPlatinum-based chemotherapySymptom burdenPotential risk factorsVegetable/fruit intakeWHO criteriaChemotherapy cyclesAlcohol intakeSmoking historyUnivariate analysisChemotherapyMultivariate regression modelMedical historyTreatment characteristicsNeurotoxic chemotherapyKey risk factorsNeuropathyCancer CenterSide effectsQuality of lifeTreatment decisionsAre we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy
Molassiotis A, Cheng H, Lopez V, Au J, Chan A, Bandla A, Leung K, Li Y, Wong K, Suen L, Chan C, Yorke J, Farrell C, Sundar R. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy. BMC Cancer 2019, 19: 132. PMID: 30736741, PMCID: PMC6368751, DOI: 10.1186/s12885-019-5302-4.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCohort StudiesDose-Response Relationship, DrugFemaleHumansLongitudinal StudiesMaleMiddle AgedNeoplasm StagingNeoplasmsPatient Reported Outcome MeasuresPeripheral Nervous System DiseasesPrevalenceProspective StudiesQuality of LifeSeverity of Illness IndexConceptsChemotherapy-induced peripheral neuropathyPeripheral neuropathyNeurotoxic chemotherapyPrevalence of sensory neuropathyCohort study of patientsCumulative chemotherapy dosePlatinum-based chemotherapyLongitudinal cohort study of patientsMeasuring chemotherapy-induced peripheral neuropathyStudy of patientsNerve conduction studiesAssessment of chemotherapy-induced peripheral neuropathyCIPN incidencePatient-reported outcome measuresAssociated with onsetLongitudinal cohort studyChemotherapy doseMotor neurotoxicityClinician-based scalesMotor neuropathySensory neuropathyChemotherapyNeuropathyNatural historyPatients
2018
Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept “3G” Trial
Yong W, Rha S, Tan I, Choo S, Syn N, Koh V, Tan S, Asuncion B, Sundar R, So J, Shabbir A, Tan C, Kim H, Jung M, Chung H, Ng M, Tai D, Lee M, Wu J, Yeoh K, Tan P, Consortium O. Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept “3G” Trial. Clinical Cancer Research 2018, 24: 5272-5281. PMID: 30045931, DOI: 10.1158/1078-0432.ccr-18-0193.Peer-Reviewed Original ResearchConceptsGenomic classifierManagement of advanced gastric cancerGastric cancerS-1 regimenOpen-label phaseAdvanced gastric cancerGastric cancer chemotherapySensitivity to oxaliplatinTreated with cisplatinTumor gene expressionMedian turnaround timeTreated with SPGene expression signaturesSOX chemotherapyPatient tumorsTreatment stratificationStratify patientsMetabolic signaturesChemotherapyGene expression profilesOxaliplatinPatientsCancer chemotherapyPredictive valueResponse rate
2015
Nivolumab in NSCLC: latest evidence and clinical potential
Sundar R, Cho B, Brahmer J, Soo R. Nivolumab in NSCLC: latest evidence and clinical potential. Therapeutic Advances In Medical Oncology 2015, 7: 85-96. PMID: 25755681, PMCID: PMC4346216, DOI: 10.1177/1758834014567470.Peer-Reviewed Original ResearchNon-small cell lung cancerStudy of nivolumabImmune checkpoint modulatorsPD-1 inhibitorsCell lung cancerMolecular targeted therapyTreatment of patientsEarly phase studiesHost immune responseUnresectable melanomaPD-1Checkpoint modulatorsSolid tumorsNivolumabEvading host immune responsesImmune modulationLung cancerImmune responseClinical potentialImmune systemLigand pathwayRegulatory approvalTumorPatientsChemotherapy